Anxiolytic action of CGS 9896 on mouse exploratory behavior

Courtney B. Smith, Jacqueline Crawley

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

A new non-benzodiazepine compound proposed as a non-sedating anxiolytic was tested in the mouse exploratory model of anxiety. CGS 9896 significantly increased the number of light dark transitions at doses beginning at 7.5 mg/kg i.p. Analysis of general locomotor activity at these doses revealed no change in spontaneous motor activity in a photocell equipped activity monitor. Pretreatment with the benzodiazepine receptor antagonist, Ro15-1788, 10 mg/kg i.p., blocked the increase in light dark transitions produced by CGS 9896. These data support the interpretation that CGS 9896 acts as an anxiolytic through the benzodiazepine receptor, and appears to have no sedating properties within the anxiolytic dose range.

Original languageEnglish (US)
Pages (from-to)259-262
Number of pages4
JournalEuropean Journal of Pharmacology
Volume132
Issue number2-3
DOIs
StatePublished - Dec 16 1986
Externally publishedYes

Fingerprint

Exploratory Behavior
Anti-Anxiety Agents
GABA-A Receptors
Light
Locomotion
Motor Activity
Anxiety
2-(4-chlorophenyl)-2,5-dihydropyrazolo(4,3-c)quinoline-3(3H)-one

Keywords

  • (Mouse)
  • Anxiety
  • Benzodiazepine receptor
  • CGS 9896
  • Exploration
  • Sedation

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Anxiolytic action of CGS 9896 on mouse exploratory behavior. / Smith, Courtney B.; Crawley, Jacqueline.

In: European Journal of Pharmacology, Vol. 132, No. 2-3, 16.12.1986, p. 259-262.

Research output: Contribution to journalArticle

@article{9c6b99d34af5497ab972ace334bde60d,
title = "Anxiolytic action of CGS 9896 on mouse exploratory behavior",
abstract = "A new non-benzodiazepine compound proposed as a non-sedating anxiolytic was tested in the mouse exploratory model of anxiety. CGS 9896 significantly increased the number of light dark transitions at doses beginning at 7.5 mg/kg i.p. Analysis of general locomotor activity at these doses revealed no change in spontaneous motor activity in a photocell equipped activity monitor. Pretreatment with the benzodiazepine receptor antagonist, Ro15-1788, 10 mg/kg i.p., blocked the increase in light dark transitions produced by CGS 9896. These data support the interpretation that CGS 9896 acts as an anxiolytic through the benzodiazepine receptor, and appears to have no sedating properties within the anxiolytic dose range.",
keywords = "(Mouse), Anxiety, Benzodiazepine receptor, CGS 9896, Exploration, Sedation",
author = "Smith, {Courtney B.} and Jacqueline Crawley",
year = "1986",
month = "12",
day = "16",
doi = "10.1016/0014-2999(86)90613-8",
language = "English (US)",
volume = "132",
pages = "259--262",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Anxiolytic action of CGS 9896 on mouse exploratory behavior

AU - Smith, Courtney B.

AU - Crawley, Jacqueline

PY - 1986/12/16

Y1 - 1986/12/16

N2 - A new non-benzodiazepine compound proposed as a non-sedating anxiolytic was tested in the mouse exploratory model of anxiety. CGS 9896 significantly increased the number of light dark transitions at doses beginning at 7.5 mg/kg i.p. Analysis of general locomotor activity at these doses revealed no change in spontaneous motor activity in a photocell equipped activity monitor. Pretreatment with the benzodiazepine receptor antagonist, Ro15-1788, 10 mg/kg i.p., blocked the increase in light dark transitions produced by CGS 9896. These data support the interpretation that CGS 9896 acts as an anxiolytic through the benzodiazepine receptor, and appears to have no sedating properties within the anxiolytic dose range.

AB - A new non-benzodiazepine compound proposed as a non-sedating anxiolytic was tested in the mouse exploratory model of anxiety. CGS 9896 significantly increased the number of light dark transitions at doses beginning at 7.5 mg/kg i.p. Analysis of general locomotor activity at these doses revealed no change in spontaneous motor activity in a photocell equipped activity monitor. Pretreatment with the benzodiazepine receptor antagonist, Ro15-1788, 10 mg/kg i.p., blocked the increase in light dark transitions produced by CGS 9896. These data support the interpretation that CGS 9896 acts as an anxiolytic through the benzodiazepine receptor, and appears to have no sedating properties within the anxiolytic dose range.

KW - (Mouse)

KW - Anxiety

KW - Benzodiazepine receptor

KW - CGS 9896

KW - Exploration

KW - Sedation

UR - http://www.scopus.com/inward/record.url?scp=0022897864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022897864&partnerID=8YFLogxK

U2 - 10.1016/0014-2999(86)90613-8

DO - 10.1016/0014-2999(86)90613-8

M3 - Article

C2 - 2880734

AN - SCOPUS:0022897864

VL - 132

SP - 259

EP - 262

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -